You are here: Industry Insights > haemophilia A

News List

Octapharma puts a spotlight on the challenges of managing inhibitors in haemophilia A at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) prnasia
January 20, 2022
The virtual symposium held on Wednesday, February 2, 2022, at 18:00 CET, will tell the story of the Rodriguez family and their two sons with haemophilia A as they navigate the challenges of inhibitor management.
Gene therapy sustains bleeding control in haemophilia A trial EuropeanPharmaceuticalReview
December 15, 2021
Giroctocogene fitelparvovec had a mean annualised bleeding rate (ABR) of just 1.4 percent over two years, with no bleeding events in the first year post infusion.
New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A expresspharma
July 21, 2021
Final analysis from the phase-IIIb STASEY study, including data from 193 people with haemophilia A, further supports the benefit/risk profile of Hemlibra, with no new safety signals identified.
BioMarin resubmits haemophilia A gene therapy to the EMA pharmatimes
June 30, 2021
BioMarin has resubmitted a marketing authorisation application (MAA) for its haemophilia A gene therapy valoctocogene roxaparvovec to the European Medicines Agency (EMA), the company announced 28th.
Successful Eloctaq bid should widen access to the drug in the UK pharmatimes
June 30, 2020
The National Health Service (NHS) and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Eloctaq (efmoroctocog alfa), by lifting prior volume restrictions for the drug.
EU gives Bayer's Jivi the green light November 29, 2018
Jivi (formerly BAY94-9027) has been approved by the European Commission for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older...
Bayer's Jivi garners EU approval for treatment, prophylaxis of haemophilia A firstwordpharma
November 28, 2018
Bayer said Tuesday that the European Commission approved the recombinant Factor VIII (rFVIII) replacement therapy Jivi for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older with haemophilia A. The therapy, f
Bayer's Jivi garners EU approval for treatment, prophylaxis of haemophilia A firstwordpharma
November 28, 2018
Bayer said Tuesday that the European Commission approved the recombinant Factor VIII (rFVIII) replacement therapy Jivi for the treatment and prophylaxis of bleeding in previously treated patients 12 years of age or older with haemophilia A. The therapy, f
Use of Roche’s haemophilia A therapy Hemlibra expanded in the US pharmatimes
October 11, 2018
Roche’s Hemlibra has been approved in the US for routine prophylaxis of bleeding episodes patients with haemophilia A without factor VIII inhibitors.
Roche’s Hemlibra secures extended FDA approval for haemophilia A pharmaceutical-technology
October 09, 2018
Roche has secured approval from the US Food and Drug Administration (FDA) for the use of Hemlibra (emicizumab-kxwh) to treat haemophilia A patients without factor VIII inhibitors.

Previous page 1 2 Next page